Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal

Business & Economics

• Hepatitis C 100%
• Cost-effectiveness Analysis 74%
• Virus 72%
• Genotype 70%
• Liver 63%
• Quality-adjusted Life Years 55%
• Portugal 54%
• Infection 53%
• Health State 45%
• Costs 15%
• Markov Model 13%
• Burden of Disease 12%
• Cost-effectiveness Ratio 11%
• Protease 10%
• Incremental Cost 10%
• Robustness 10%
• Life Expectancy 10%
• Clinical Trials 9%
• Inhibitor 9%
• Systems Perspective 9%
• Product Characteristics 9%
• Transplantation 9%
• Resource Use 9%
• Cohort 9%
• Unit Cost 9%
• Health Care System 8%
• Cost-effectiveness 8%
• Discount Rate 8%
• Medicine 5%

Medicine & Life Sciences

• N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide 89%
• Portugal 71%
• Chronic Hepatitis C 60%
• Hepacivirus 53%
• Cost-Benefit Analysis 49%
• Ribavirin 48%
• Genotype 41%
• Quality-Adjusted Life Years 39%
• Infections 27%
• Costs and Cost Analysis 22%
• Health Care Costs 12%
• Liver 11%
• telaprevir 10%
• Fibrosis 10%
• Sustained Virologic Response 9%
• Therapeutics 9%
• Health Resources 8%
• Protease Inhibitors 7%
• Natural History 7%
• Life Expectancy 7%
• Health 7%
• Liver Transplantation 6%
• Liver Diseases 6%
• Clinical Trials 4%
• Delivery of Health Care 4%
• Incidence 3%

Social Sciences

• contagious disease 56%
• Portugal 55%
• life years 42%
• costs 32%
• health 11%
• death 9%
• clinical outcomes 8%
• Clinical Trials 6%
• life expectancy 6%
• incidence 5%
• medicine 4%
• expert 4%
• history 3%
• management 3%
• resources 2%
• experience 1%